Kevin Bunting, PhD

Titles and Roles

Associate Professor, Department of Pediatrics, Division of Hematology/Oncology/Bone Marrow Transplant & Aflac Cancer and Blood Disorders Center
Emory University School of Medicine
Aflac Field Force Cancer Innovative Therapy Chair
Emory University School of Medicine
Research Program
Cancer Cell Biology


Dr. Bunting is a member of the American Society of Hematology, the American Association for Cancer Research, and the American Association for the Advancement of Science. 


Dr. Bunting earned his medical degree from Wake Forest University in Winston-Salem, North Carolina. He then went on to complete a fellowship in Experimental Hematology at St. Jude Children’s Research Hospital in Memphis, Tennessee. 


Dr. Buntington has received the Emory Millipub Club, 2013 Award.


Dr. Bunting's research is focused on understanding the biology of the latent transcription factor STAT5, in particular its roles in normal hematopoietic stem cell function and its aberrant activation associated with a variety of hematologic malignancies. Activation of STAT5 by phosphorylation is required at tightly regulated levels for normal hematopoiesis but its persistent activation is prevalent in adult and pediatric leukemias. A major focus of the Bunting lab is to identify keySTAT5 downstream target genes associated with both normal and leukemic hematopoietic cell function and to utilize this knowledge to develop novel approaches to manipulate STAT5 activity in a therapeutic setting. In leukemia therapy, the goal is to disengage leukemic cell survival and to facilitate leukemia cell sensitivity in combination with other targeted agents. In hematopoietic stem cell transplantation, the goal is to develop innovative forms of conditioning based on STAT5 signaling inhibition.


Dr. Bunting has authored/co-authored 108 publications, 62 journal articles and 46 journal abstracts. 

Cascade Link